RemeGen

News

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

AbbVie joins the ranks of companies developing cancer drugs that target both PD-1 and VEGF, via a $5.6bn licensing deal with China's RemeGen.

News

More good news in Sjogren's as RemeGen trial delivers

A second new drug, RemeGen's telitacicept, has shown efficacy in a phase 3 Sjögren's syndrome trial in the space of a week.

News

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

After winding up its stem cell therapy operations last month, Vor Bio has reinvented itself as an autoimmune disease-focused biotech.

News

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

Seagen is a specialist in antibody-drug conjugates, but has looked to Chinese biotech RemeGen for a HER2-targeting candidate that could challenge rival drugs from AstraZeneca/Daiichi Sankyo

JPM: AbbVie pays $650m upfront for RemeGen cancer drug

More good news in Sjogren's as RemeGen trial delivers

Vor Bio revives, thanks to $4bn+ licensing deal with RemeGen

HER2 heats up as Seagen licenses RemeGen ADC for $2.6bn

ASCO 2026: Chinese firms take a front seat in oncology, with...

Discover a new era of healthcare panel engagement: Grounded ...

RemeGen

Editor's Picks